Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Division of Allergy and Clinical Immunology, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA.
J Infect Dis. 2022 Nov 11;226(10):1852-1856. doi: 10.1093/infdis/jiac339.
In mice, pneumococcal polysaccharide (PPS) vaccines generate antigen-specific immunoglobulin M (IgM) and immunoglobulins G1, G2, and G3. Antibody and complement-dependent opsonophagocytosis correlates with the protection induced by PPS vaccines in vivo. Since IgM is a very efficient immunoglobulin isotype in activating the complement system, we evaluated whether anti-PPS IgM alone is sufficient to confer protective immunity to Streptococcus pneumoniae. We found that immunization of wild-type and activation-induced cytidine deaminase-deficient mice capable of producing only IgM with Pneumovax 23 generated comparable anti-PPS IgM and resistance to lethal systemic challenge with S pneumoniae. These data suggest that an IgM response to PPS vaccines is sufficient for conferring immunity.
在小鼠中，肺炎球菌多糖（PPS）疫苗可产生抗原特异性免疫球蛋白 M（IgM）和免疫球蛋白 G1、G2 和 G3。抗体和补体依赖性调理吞噬作用与 PPS 疫苗在体内诱导的保护作用相关。由于 IgM 是一种非常有效的免疫球蛋白亚型，可激活补体系统，因此我们评估了仅抗 PPS IgM 是否足以赋予肺炎链球菌保护性免疫。我们发现，用 Pneumovax 23 对仅能产生 IgM 的野生型和激活诱导的胞苷脱氨酶缺陷型小鼠进行免疫接种，可产生相当的抗 PPS IgM 并抵抗致死性系统性肺炎链球菌攻击。这些数据表明，对 PPS 疫苗的 IgM 反应足以赋予免疫力。
